Results 191 to 200 of about 2,645,233 (222)

Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis

Arthritis &Rheumatology, Accepted Article.
Objectives Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, relapsing, inflammatory disease. Management of EGPA predominantly relies on oral corticosteroids (OCS), which are associated with many adverse effects. The Phase III MIRRA trial demonstrated efficacy and safety of mepolizumab, anti‐interleukin‐5 biologic, for EGPA.
Michael E Wechsler, Jared Silver, Gerhard Wolff, Robert G Price, Rejina Verghis, Peter F Weller, Peter A Merkel, Paneez Khoury, on behalf of the EGPA Mepolizumab Open‐Label Extension study group, Arnaud Bourdin, Pascal Chanez, Anoop Chauhan, Vincent Cottin, Gerald Gleich, Berhnard Hellmich, Tomonori Ishii, David Jayne, Jean‐Emmanuel Kahn, Peter Kern, Nader Khalidi, Ina Koetter, Carol Langford, Amy Markezich, Paul Monach, Shamsa Naveed, Peter Oelzner, Kenneth Pinna, Xavier Puechal, Emory H Robinette, Florence Roufosse, Reinhard Voll, Andrew Schafer, Kaharu Sumino, Masami Taniguchi, Phillip Lieberman   +34 more
wiley   +1 more source

Pulmonary function course. V. Respiratory organ nuclear medicine.

Japanese Journal of Pediatric Pulmonology, 1996
openaire   +3 more sources

Effects of combined Chinese and Western medicine treatment on lung respiratory function in patients with chronic obstructive pulmonary disease

Asian Journal of Surgery
Daohui Gan, Dezhi Li, Lvyu Deng, Li Liu
openaire   +3 more sources

Clinical factors associated with pneumocystis pneumonia despite its primary prophylaxis: When to stop prophylaxis?

Arthritis &Rheumatology, Accepted Article.
Objective Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is effective in patients with rheumatic diseases receiving immunosuppressive treatment, there is limited evidence regarding the optimal timing for prophylaxis withdrawal.
Ju Yeon Kim, Se Rim Choi, Jin Kyun Park, Eun Young Lee, Eun Bong Lee, Jun Won Park   +5 more
wiley   +1 more source

International Journal of Respiratory and Pulmonary Medicine – A New Place to Publish Basic and Clinical Lung Research

International Journal of Respiratory and Pulmonary Medicine, 2015
openaire   +2 more sources

Factors influencing physicians’ antimicrobial prescribing decisions: A systematic review of qualitative studies

British Journal of Clinical Pharmacology, EarlyView.
Inappropriate and overuse of antimicrobials is increasing antimicrobial resistance. Understanding physicians' antimicrobial decision‐making is essential for developing interventions to optimize prescribing. The aim of this review was to identify the factors that influence physicians' antimicrobial prescribing decisions.
Savannah Reali, Yee Chin Kwang, Jin‐Gun Cho, Jan‐Willem Alffenaar, Parisa Aslani   +4 more
wiley   +1 more source

Adverse events associated with monoclonal antibodies used for treatment of COVID‐19: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims This review aimed to synthesise the evidence related to the incidence of serious and non‐serious adverse events with the use of monoclonal antibodies (mAbs) among COVID‐19 patients. Methods Databases were searched from January 2020 to September 2023 for randomized clinical trials (RCTs) that used mAbs for the treatment of COVID‐19 regardless of ...
Htet Htet, Han You Kyung, Ismail Abdul Sattar Burud, Heethal Jaiprakash, Thiruselvi Subramaniam, Igor Iezhitsa, Renu Agarwal   +6 more
wiley   +1 more source

Safety of sulfamethoxazole–trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta‐analysis with active comparator disproportionality analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Sulfamethoxazole–trimethoprim (SMX‐TMP) is a widely used antibiotic for treating bacterial infections, but its safety in adult outpatients remains understudied. This systematic review and meta‐analysis evaluated the safety profile of SMX‐TMP and identified critical research gaps.
Rebecca Preyra, Lujain Ez Eddin, Fatemeh Ahmadi, Atefeh Jafari, Flory T. Muanda   +4 more
wiley   +1 more source

Journal of Pulmonary Medicine and Respiratory Diseases

, 2018
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pulmonary arteriovenous malformations- Evidence of under recognition in respiratory medicine?

4.3 Pulmonary Circulation and Pulmonary Vascular Diseases, 2016
Introduction: Pulmonary arteriovenous malformations (AVMs) affect ∼1 in 2,600 people and pose unique management challenges. Methods: US and UK Training curriculae were examined. PubMed searches were performed for “pulmonary arteriovenous malformations” or pulmonary arterial hypertension” with specified date ranges, with and without the filter ”case
James R. Gossage, Claire L. Shovlin
openaire   +2 more sources